Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mentice ABFRA:MN2 -4.15%75 Days Payable is 87.06 as of Jun. 2026, which is 40% below its 10-year median of 146.11. GuruFocus rates FRA:MN2 with a GF Score™ of 75/100 and a GF Value™ of €1.91 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Mentice AB ranks better than 60.75% on this metric.
Mentice AB's average Accounts Payable for the
three
months ended in Jun. 2026 was €0.76 Mil. Mentice AB's Cost of Goods Sold for the
three
months ended in Jun. 2026 was €0.80 Mil.
Hence, Mentice AB's Days Payable for the
three
months ended in Jun. 2026 was 87.06.
The historical rank and industry rank for Mentice AB's Days Payable or its related term are showing as below:
FRA:MN2'
s Days Payable Range Over the Past 10 Years
Min: 90.03 Med: 146.11 Max: 157.33
Current: 90.03
During the past 9 years, Mentice AB's highest Days Payable was 157.33. The lowest was 90.03. And the median was 146.11.
FRA:MN2's Days Payable is ranked better than 60.75% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.21
vs FRA:MN2: 90.03
Mentice AB's Days Payable
declined
from Jun. 2025 (137.05) to Jun. 2026 (87.06).
It may suggest that Mentice ABaccelerated paying its suppliers.
The historical data trend for Mentice AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Mentice AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mentice AB Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mentice AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Mentice AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Mentice AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mentice AB (FRA:MN2) has a Days Payable of 87.06 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mentice AB and its competitors. This is 40% below median its historical median of 146.11. Over the past decade, Mentice AB's Days Payable has ranged from 90.03 to 157.33. According to the industry distribution chart, Mentice AB ranks #312 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 39.2%.
Is Mentice AB's Days Payable too high?
Mentice AB's current Days Payable of 87.06 is 40% below median its 10-year median of 146.11. Over the past 10 years, this metric has ranged from a low of 90.03 to a high of 157.33. The Medical Devices & Instruments industry median Days Payable is 68.21. Mentice AB's value of 87.06 is 27.6% above this industry median. Based on the distribution chart, Mentice AB ranks #312 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Mentice AB has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mentice AB's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Mentice AB ranks #312 out of 795 companies for Days Payable. This puts Mentice AB in the upper half of its industry. The industry median Days Payable is 68.21. Mentice AB's value of 87.06 is 27.6% above this benchmark. Historically, Mentice AB's own Days Payable has ranged from 90.03 to 157.33 over the past decade. While the company's 10-year median is 146.11 vs. the industry median of 68.21, Mentice AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.21, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mentice AB's current Days Payable of 87.06 is 27.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mentice AB and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mentice AB's current Days Payable is 87.06, which is 40% below median its own 10-year median of 146.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mentice AB stock overvalued right now?
Based on GuruFocus' analysis, Mentice AB (FRA:MN2) is currently considered Significantly Undervalued. The stock's GF Value™ is €1.91, compared to a current price of €1.27 — trading 33.5% below its estimated fair value. The current Days Payable is 87.06, which is 40% below median its 10-year median of 146.11 and 27.6% above the Medical Devices & Instruments industry median of 68.21. Mentice AB's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Mentice AB (FRA:MN2), the current Days Payable is 87.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mentice AB (FRA:MN2) Overvalued in 2026?
Based on GuruFocus' analysis, Mentice AB stock appears to be undervalued.
The current stock price of €1.27 is trading 33.5% below its estimated GF Value™ of €1.91.
GuruFocus considers Mentice AB to be Significantly Undervalued.
Key valuation signals for FRA:MN2:
Days Payable: 87.06 (40% below median its 10-year median of 146.11)
GF Value™: €1.91 vs. price of €1.27 (33.5% below fair value)
Industry Position: 27.6% above the Medical Devices & Instruments median (#312 of 795)
No single metric tells the full story. See the FRA:MN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mentice AB is a provider of software and hardware simulation solutions for image guided interventional therapies, offering proficiency based simulation solutions that help healthcare professionals acquire, retain, and enhance procedural skills, improving productivity and outcomes. Its solutions are scientifically validated and developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are covered. Mentice operates in two segments: Medical Device Industry (MDI), providing end-to-end solutions supporting development and launch of interventional therapies, and Healthcare Systems (HCS). Product areas include Mentice VIST, Physical Sim, Mentice Live, and Ankyras. It operates in EMEA, APAC, and the Americas.
75GF Score
Get the complete analysis for FRA:MN2
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MN2 has been successfully added to your 
